R ett syndrome is a rare and devastating condition that results in intellectual and physical disability, and mainly affects females. Nearly all diagnosed cases are associated with mutations in the MECP2 gene that cause its encoded protein to become non-functional or to be present in reduced amounts 1 . However, because the MECP2 protein interacts with many other proteins and has both broad and specific roles in the regulation of gene expression, determining how MECP2 loss causes Rett syndrome has been difficult. On page 398, Tillotson et al. 2 report that expression of a version of mouse MeCP2 that contains just two key domains is associated with reduced symptoms in a mouse model of Rett syndrome, a finding that has therapeutic implications.
Rett syndrome is usually diagnosed when atypical movement and cognitive symptoms appear in infants at 6-18 months of age. It was initially assumed that the neurological symptoms of this condition reflect abnormal brain development that would probably be challenging to reverse. However, some experiments using animal models of the disease suggest that effective therapeutic intervention might be possible. Mice genetically engineered to carry disease-associated mutations in the Mecp2 gene 3 provide models for studying Rett syndrome; the animals display key characteristics of the condition, including movement and breathing abnormalities and premature death in males. When genetic engineering was used to induce MeCP2 expression in adult mice that had lacked the protein, some of the most severe effects of the syndrome, including the incidence of movement abnormalities and premature death, were reduced 4 . Another study 5 confirmed that MeCP2 expression is required for normal brain function, because deleting Mecp2 in adult mice induced behavioural problems and premature death. Such studies raised hopes that, even after symptoms have appeared, therapies to restore MECP2 function might improve the lives of people with Rett syndrome 6 . However, restoring MECP2 expression in patients poses technical challenges, and the uncertainty about the specific way in which the protein prevents the condition is another hurdle to overcome.
MeCP2 contains several different domains, each with distinct roles. For example, the methyl-DNA binding domain (MBD) binds cytosine DNA bases that have a methyl group attached. Methylation of DNA that is in complex with histone proteins in a structure called chromatin is often associated with gene-expression changes, and it is presumed that MeCP2 can aid this regulatory process 3 .
Other domains in MeCP2 are evolutionarily conserved, and mediate many other types of molecular interaction; for example, the protein's AT-hook domains can directly contact DNA. MeCP2 can also bind proteins that regulate gene expression through a range of mechanisms, including chromatin modification and RNA regulation 3 . Although these observations indicate that MeCP2 functions as a scaffold to coordinate many processes of gene regulation, most missense mutations associated with Rett syndrome (those in which one amino acid is different from the wild-type version) occur either in the MBD
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Domains to the rescue for Rett syndrome
Rett syndrome is a brain disorder caused by disrupted forms of the protein MECP2, but how MECP2 loss affects the brain is unknown. A mouse study now implicates key domains of the protein and offers therapeutic insights. See Letter p.398 technique called the DNA curtain assay.
Zhao and colleagues identified a site in the BARD1 subunit with which RAD51 interacts with high affinity. This allowed them to construct a mutant version of the BRCA1-BARD1 complex in which three amino-acid residues in BARD1 had been replaced by others, impairing the complex's association with RAD51 in vitro and in vivo. The authors observed that the mutant (known as BRCA1-BARD1 AAE ) impairs stimulation of recombination in the D-loop assay, or complex assembly in the DNA curtain assay.
When the researchers transiently replaced the wild-type BRCA1-BARD1 complex with BRCA1-BARD1 AAE in cultured human cells, they observed defects in recombination assays. Furthermore, the cells could be killed by the compound mitomycin C and by an inhibitor of the PARP enzyme; cell sensitivities to mitomycin C and PARP inhibitors are hallmarks of impaired recombination. These experiments convincingly demonstrate that the mechanistic insights provided by the cell-free reactions with purified proteins in vitro are functionally relevant, and that the interplay of BRCA1-BARD1 with RAD51 is important for recombination in living cells.
How does the BRCA1-BARD1 complex function alongside other RAD51 regulators? Zhao et al. performed a D-loop assay using short ssDNA pre-bound with RPA. They found that D-loop formation was more robust when BRCA1-BARD1 and BRCA2-DSS1 were both present. This confirms the separate functions of the BRCA complexes: BRCA2 stimulates the exchange of RPA for RAD51 on ssDNA 5, 9, 10 , and BRCA1 subsequently promotes DNA invasion (Fig. 1c) .
It will now be of interest to study the function of the PALB2 protein that brings the BRCA1 and BRCA2 complexes together 3 , and to delineate the interplay of these complexes with RAD51 'paralogue' proteins 11, 12 , which probably also act downstream of RAD51-ssDNA filament formation in recombination 11 . The availability of the purified BRCA1-BARD1 complex will also help scientists to work out its functions in other steps of the recombination pathway, such as the initial processing of the broken DNA ends to generate overhanging 
